


Dehydroepiandrosterone (DHEA) Capsule Separation with HPLC - AppNote

Excellent separation from matrix excipients

Pharmaceutical formulations may contain a number of excipients that can potentially interfere with a chromatographic analysis. However, using the Cogent Bidentate C8 Column, the DHEA peak is well-resolved from the others, the latter of which all elute as a large peak in the solvent front portion of the run. The API is hydrophobic and therefore retains well in the Reversed Phase mode. The use of this Column and associated conditions may be suitable for the routine assay analysis of DHEA capsule formulations.



Method Conditions

Column: Cogent Bidentate C8™, 4µm, 100Å

Catalog No.: 40008-75P Dimensions: 4.6 x 75 mm

Solvents:

A: 90% Water/ 10% Acetonitrile/ 0.1% Formic Acid (v/v)

B: Acetonitrile/ 0.1% Formic Acid (v/v)

Mobile Phase: 60% A/ 40% B

Injection vol.: 5µL Flow rate: 1 mL/minute Detection: UV 205 nm

Sample: 500 mg strength DHEA capsule contents were added to a 50 mL volumetric flask containing a portion of Methanol diluent. The contents were sonicated for 10 min, diluted to mark, and mixed

thoroughly. Then a portion was filtered (0.45µm, nylon) for injections.

Notes: DHEA is a metabolic precursor to various sex hormones. It can be used in hormone replacement therapy. Evidence for some other purported benefits such as promotion of muscle growth, memory improvement, and antisenescence effects is currently lacking.



Attachment

No 364 Dehydroepiandrosterone DHEA Capsule.pdf 0.1 Mb Download File

Printed from the Chrom Resource Center
Copyright 2025, All Rights Apply
MicroSolv Technology Corporation
9158 Industrial Blvd. NE, Leland, NC 28451

Tel: (732) 380-8900
Fax: (910) 769-9435
Email: customers@mtc-usa.com
Website: www.mtc-usa.com